ArticleScientific reports2026
TMEM92 drives EMT-associated invasiveness, cisplatin resistance, and immune suppression in head and neck squamous cell carcinoma.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Transmembrane protein 92 (TMEM92) has been implicated in tumor progression in several malignancies, yet its role in head and neck squamous cell carcinoma (HNSCC) remains unclear. Here, we systematically investigated the expression pattern, clinical relevance, and biological functions of TMEM92 in HNSCC. Transcriptomic and clinical data from TCGA and GEO were analysed, including bulk, single-cell, and spatial transcriptomic data from GEO. TMEM92 was significantly upregulated in HNSCC, particularly in HPV-negative tumors, and high TMEM92 expression was independently associated with poor overall survival. Single-cell analysis revealed that TMEM92 expression was predominantly enriched in malignant cells. Functional analyses and in vitro experiments demonstrated that TMEM92 promoted cell proliferation, migration, invasion, epithelial–mesenchymal transition (EMT), and cisplatin resistance. Moreover, elevated TMEM92 expression was associated with lymph node metastasis, an immunosuppressive tumor microenvironment, and a poor predicted response to immunotherapy. These findings suggest that TMEM92 plays a critical role in HNSCC progression and may serve as a potential prognostic biomarker and therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.